Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China-based Sihuan Pharmaceutical announced the opening of new production and R&D centre in the Zhangwan Development Area, Tongzhou District, Beijing.
Subscribe to our email newsletter
The new facility which will occupy 175 acres of area will commence production in August 2013
The first phase will comprise production lines with an annual capacity of 300 million vials of small volume liquid for injection, 20 million vials of lyophilised powder for injection and 20 million vials of sterile powder for injection.
The facilities will comply with the new Chinese Good Manufacturing Practice (GMP) standards and selected production lines will also conform with US Food and Drug Administration (FDA) standards, the company said.
Sihuan chairman and CEO Che Fengsheng said the new production plant and R&D centre will strengthen their production capacity and R&D capabilities thereby enabling their growth.
"To ensure that our products are of the highest quality and conform to the new GMP requirements, we are also upgrading our biological medicine and traditional Chinese medicine production plant in Jilin," Fengsheng added.